Log in
/
Register
Home
Overview
Upload / Manage Data
Browse / Search Studies
Analyze Studies
Tutorials
FAQ
Data Repository
Overview
Upload / Manage Studies
Browse / Search Studies
Analyze Studies
Data Sharing Policy
Tutorials
FAQ
Databases
Overview
RefMet: Metabolite Nomenclature
Metabolite Database
Human Metabolome Gene/Protein Database (MGP)
External Metabolomics Databases (Links)
Protocols
Overview
General Protocols
Study-specific Protocols
Tools
Overview
Load and analyze your own dataset
Analyze Studies
MS Searches
Structure drawing
REST Service
External Tools (Links)
About
Overview
Publishing Partners
How to Cite
How to Link
Terms of Use
Personnel
Contact
Sitemap
Search
Keyword Search
Advanced Searches
Clustering data with hclust algorithm for (Study ST001795)
Reversed phase NEGATIVE ION MODE (Analysis AN002916)
Metabolite
Structure
F1
F2
F3
FA (22:5)
ME416863
0.75
1.24
1.03
Aeruginopeptin 917S-C
ME416816
1.01
0.85
1.12
[FA (22:4)] 7Z_10Z_13Z_16Z-docosatetraenoic acid
ME416838
0.98
0.95
1.07
Cholesterolsulfate
ME416807
1.04
0.79
1.15
FA(16:1)
ME416858
1.04
1.02
0.94
beta-Tocotrienol
ME416717
1.05
0.04
1.79
FA hydroxy(18:0)
ME416731
1.17
0.32
1.44
FA methyl(16:1)
ME416882
0.84
1.41
0.80
1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-cytidine-5^- diphosphate
ME416716
1.08
NA
0.92
Cer(t18:0/h24:0)
ME416853
0.86
1.10
1.05
bafilomycin A1
ME416905
0.56
1.86
0.68
CGS 7181
ME416872
0.98
1.19
0.85
FA hydroxy (18:2)
ME416921
0.40
2.41
0.35
Citrate
ME416786
1.30
0.61
1.04
(4Z_7Z_10Z_13Z_16Z_19Z)-Docosahexaenoic acid ethyl ester
ME416871
0.94
1.21
0.87
Cyanidin 3-(6-acetylgalactoside)
ME416817
1.01
0.85
1.12
Decoside
ME416710
0.90
NA
1.08
Docosahexaenoicacid
ME416789
1.08
0.71
1.18
Dodecanoic acid
ME416721
1.43
0.08
1.39
FA (20:0)
ME416761
1.19
0.53
1.23
FA hydroxy(20:1)
ME416802
1.08
0.76
1.13
3-O-(6^-O-(9Z_12Z_15Z-octadecatrienoyl)-beta-D-glucopyranosyl)-campest-5-en-3beta-ol
ME416849
1.07
0.95
0.97
Docosanoic acid
ME416779
1.10
0.66
1.21
[FA (34:2)] 1-octadecyl-11E-hexadecenoate
ME416906
0.44
1.96
0.71
2-heptaprenyl-3-methyl-6-methoxy-1_4-benzoquinol
ME416788
1.13
0.69
1.14
3-O-(6^-O-(11Z_14Z_17Z-eicosatrienoyl)-beta-D-glucopyranosyl)-campest-5-en-3beta-ol
ME416840
1.14
0.87
0.98
Arachidyl palmitoleate
ME416907
0.38
1.91
0.68
FA (18:1)
ME416759
1.24
0.51
1.19
[FA (24:0)] 15Z-tetracosenoic acid
ME416860
0.94
1.12
0.96
FA (20:4)
ME416809
1.00
0.83
1.15
3alpha_7alpha_12alpha-Trihydroxy-5beta-cholestan-26-al
ME416923
0.17
2.90
0.15
FA (20:2)
ME416880
0.79
1.42
0.84
FA (19:1)
ME416875
0.83
1.33
0.88
FA methyl(18:0)
ME416896
0.61
1.69
0.78
FA (18:3)
ME416876
0.89
1.30
0.84
FA hydroxy(20:3)
ME416856
1.86
0.56
0.53
CDP-DG(36:2)
ME416712
1.10
NA
0.90
FA (17:0)
ME416865
0.87
1.20
0.96
FA hydroxy(18:2)
ME416819
1.01
0.87
1.11
16-feruloyloxypalmitate
ME416757
1.27
0.49
1.19
FA (22:1)
ME416828
1.05
0.88
1.06
1-18:0-2-18:3-monogalactosyldiacylglycerol
ME416837
0.96
0.95
1.08
FA (18:2)
ME416902
0.67
1.75
0.66
[FA (26:0)] hexacosanoic acid
ME416796
1.08
0.74
1.14
FA dimethyl(20:3)
ME416742
1.15
0.41
1.37
FA (20:3)
ME416833
0.91
0.97
1.12
FA (14:1) tetradecenoic acid
ME416793
1.13
0.71
1.13
4Z_7Z_10Z_13Z_16Z_19Z_22Z_25Z-octacosaoctaenoic acid
ME416713
1.02
NA
0.99
FA hydroxy(12:0) dodecanoic acid
ME416752
1.21
0.48
1.25
FA (23:1)
ME416874
0.83
1.32
0.88
FA (20:1)
ME416829
1.11
0.86
1.02
FA (16:3)
ME416835
1.12
0.87
0.99
FA hydroxy(18:1)]
ME416855
0.90
1.09
1.02
FA hydroxy(20:4)
ME416854
2.38
0.28
0.26
FA (16:2)
ME416885
0.82
1.44
0.78
FA hydroxy(22:0)
ME416781
1.14
0.65
1.17
FA (18:4)
ME416839
1.08
0.90
1.01
FA methyl(14:0)
ME416879
0.80
1.38
0.86
[FA oxo(14:0)] 3-oxo-tetradecanoic acid
ME416769
1.20
0.56
1.19
Avermectin B2b monosaccharide
ME416814
1.13
0.79
1.06
Bilirubin
ME416846
0.87
1.03
1.09
1_2-di-S-octyl-1_2-dimercapto-3-propanol
ME416804
1.30
0.68
0.99
FA hydroxy(18:1)
ME416898
0.91
1.49
0.65
Factors:
F1
Treatment:Celecoxib_HFD
F2
Treatment:CFD
F3
Treatment:HFD
Data matrix
UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
This repository is under review for potential modification in compliance with Administration directives
Terms of use
Site map
Contact
NMDR Personnel